Investigatio nuntiata ab investigatoribus in Universitate Fudan ostendit novam compositionem ex quattuor dapibus biomarki accurate diagnose posse pancreaticum cancer,. (Br J Cancer. Online versionem Novembrem 9, 2017).
The researchers said that we believe that the development of a fast and stable method for screening target proteins in large samples may accelerate the pace of finding new protein biomarkers and drug targets, and may even be individualized in the future. Of proteomes are used in precision medicine.
Most carcinomata sua morbi stadio progressi sunt tempore diagnosi, et rate superstes mediana post diagnosin minor est quam 6%. Primae diagnosis et curatio deploratae emendare possunt.
The researchers used a variety of mass spectrometry techniques to analyze 150 serum samples from healthy controls, patients with benign pancreatic diseases, and patients with pancreatic cancer, and identified 142 differentially expressed proteins. Finally, the four proteins were included in their biomarker expression profiles: APOE , ITIH3, APOA1 and APOL1.
Through the analysis of the area under the curve (AUC) method, the accuracy of a single protein marker used to distinguish pancreatic cancer patients from healthy controls was between 66.9% and 89.6%. The combination of the four markers can increase the accuracy to 93.7%. The sensitivity of the four-protein biomarker combination in the diagnosis of pancreatic cancer was 85%, and the specificity was 94.1%. If CA19-9 is included in this detection method, the AUC will be increased to 0.99, at which time the sensitivity is 95% and the specificity is 94.1%.
Inquisitores etiam immunohistochemistica usi sunt ad confirmandam expressionem interdum venalicium in speciminibus tumoris, ulteriorem comprobationem fidei huius novae coniunctionis biomarcae.
Investigatores dixerunt orci applicationem horum biomarkers adhuc longum iter esse. US FDA modo approbavit iuncturam analysi tumoris testium figentium ex Memorial Sloan Kettering Cancer Centrum IMPACTUM vocatum. IMPULSUS mutationes in 468 genesis et aliae hypotheticae mutationes in compositione tumoris genome humani cito deprehendere possunt.
